Divi’s Laboratories
Top executives in Indian companies made 184 times their employees in FY21
The analysis is based on a common sample of 76 companies from the Nifty 100 index
Multiple near-term concerns trigger Divi's Laboratories' headache
Pfizer's oral Covid drug, weak sales of generics, and valuations may cap upsides
Pfizer's oral Covid-19 drug may hit revenues of Divi's Laboratories
Supply of Molnupiravir to Merck was a key near-term trigger for the stock
Lack of valuation comfort may limit gains in Divi's Laboratories stock
Revenue growth prospects, however, remain strong driven by multiple factors
Strong growth prospects drive Divi's Laboratories earnings upgrades
Ongoing capacity additions, market share gains, and new launches are key triggers
Divi's Laboratories shares jump 4% after robust Jan quarter earnings
Shares of Divi's Laboratories on Monday gained 4 per cent after the company reported a 29.30 per cent rise in its consolidated net profit for the quarter ended March 31, 2021
Divi's Labs Q4 net profit jumps 29% at Rs 502 crore on robust sales
Drug firm Divi's Laboratories on Saturday reported a 29.30 percent rise in its consolidated net profit to Rs 502.02 crore for the quarter ended March 31, 2021, on account of robust sales
Divi's Lab Q4 net profit rises 25% to Rs 488 cr, aided by low base
However, the company's earnings showed strong traction in 2020-21 due to a surge in demand for bulk drugs caused by the pandemic
Project pipeline, ongoing expansion offer revenue visibility for Divi's
Divi's Laboratories Q3 results: While top line growth was strong, margin performance stood out in the December quarter
IT, pharma firms emerge Samvat 2076 winners; Infy, Divi's Lab top gainers
On the other hand, PSU stocks and banks have been laggards - with ONGC, Indian Oil, IndusInd Bank, and Coal India delivering the worst returns.
This India-focused fund beating 98% of peers targets crisis winners
According to the fund's profile, its top holding as of July 31 was drugmaker Divi's Laboratories Ltd., which has gained more than 70% in 2020
Divi's Laboratories, SBI Life Insurance shares gain on Nifty inclusion
Shares of Zee Entertainment Enterprises fell 3.7 per cent and that of Bharti Infratel ended flat. The two companies will be removed from the bluechip index
Divi's, SBI Life to see combined inflows of Rs 1,400 cr on Nifty inclusion
Over Rs 650-cr selling in Zee, Infratel
Divi's Labs: APIs, custom synthesis, ongoing capex plan to support growth
The near term upside, however, is limited given the sharp stock price run up
Nifty rejig announcement: Divi's Lab hits all-time high, SBI Life gains 4%
For the quarter ended June 2020, Divi's Lab reported a net profit of Rs 492.06 crore on account of robust sales.
SBI Life, Divi's Laboratories to move in Nifty 50 index from Sept 25
Bharti Infratel and Zee Entertainment Enterprises will be dropped from the Nifty 50, NSE Indices said in a statement
Divi's Laboratories: Margins likely to remain subdued, say analysts
Margins to get better once supplies start from expanded capacities next year
Divi's Labs Q4 net profit up 33%, total income stands at Rs 1,466 cr
The company had posted a net profit of Rs 291.97 crore for the same period previous fiscal, Divi's Labs said in a BSE filing
Divi's Labs Q2 net down 12% at Rs 357 cr; revenue rises to Rs 1446 cr
The company had posted a net profit of Rs 403.72 crore in the July-September period of 2018-19.
Divi's Labs cash in on bullish sentiment, strong growth prospects
The second largest pharma player by market value is also expanding capacities to push earnings
